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1. Introduction
In an extended review (Anscombe, 1963) of Peter Armitage’s book Sequential Medical
Trials (Armitage, 1960), Anscombe discusses a classical decision-theoretic model for
sequential clinical trials. In this model two treatments, A and B, are compared in a
sequential trial. The goal is to find an optimal rule for determining when to stop the
trial and which of the two treatments that should then be given to the remaining patient
population. In order to make the discussion of the central issues as clear as possible,
Anscombe makes a number of simplifying assumptions. We shall follow him in this. In
particular, we assume that the two treatments are indistinguishable in terms of costs
and side effects. Hence, the data provided by the trial is used solely for decreasing the
uncertainty regarding the incremental effect of A relative to B.
The present paper gives details on the underlying mathematics for solving the original
problem and proposes two different types of model extensions. The first extension follows
from the observation that, in practice, it is unrealistic that all patients in the target
population participate in the trial phase. Typically, those that are not part of the
trial will still receive some treatment (the current standard). We demonstrate that,
if it assumed that this treatment is B, then a new optimal stopping problem can be
formulated and solved with the same method used for Anscombe’s original problem. In
the other extension it is assumed that the total number of patients is no longer fixed,
but instead considered to be a random variable. The problem is identified to be of a
similar form as before. For some particular cases, the structure of the problem simplifies
substantially, allowing for explicit solutions. To the best of the authors’ knowledge, these
are the first explicit solutions in this context.
We now proceed to the formulation of Anscombe’s original problem. Assume that each
of N patients will be treated by either treatment A or B. This total number of patients
is referred to as the patient horizon and includes the subjects enrolled in the trial. Given
that XA and XB denote the responses for a patient given A and B, respectively, we
assume conditional normal distributions according to
XA ∼N
(
θ+µ,σ2
)
, XB ∼N
(
θ−µ,σ2
)
.
Here, θ denotes the mean effect of A and B in the population, while 2µ is the incremental
effect of A relative to B. Hence, µ> 0 means that treatment A is preferred to treatment
B and vice versa. The common variance parameter σ2 is assumed to be known. For a
sample size of n patients, it is assumed that half are given A and half are given B. Let
ΣAn and ΣBn denote the response sums for patients given A and B, respectively. Under
the assumption of i.i.d. normal responses given θ and µ, we have
ΣAn ∼N
(
n
2 (θ+µ),
n
2σ
2
)
, ΣBn ∼N
(
n
2 (θ−µ),
n
2σ
2
)
.
Letting the difference in response sums be denoted by Σn, it then follows that, given µ,
Σn = ΣAn −ΣBn ∼N
(
nµ,nσ2
)
.
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Based on the initial beliefs about the unknown effect parameter µ, the trial sample
size n and the observed response difference Σn, either A or B will be chosen for all
the N −n remaining patients. In practice, confirmatory (phase III) trials often have a
pre-determined sample size or use a group-sequential design with very few (one or two,
say) interim analyses. However, we will assume that the experiment is fully sequential.
Hence, the responses of each additional patient pair can be observed immediately and
we may stop the trial after any (even) number of observations.
The goal is to find an optimal rule (τ,Dτ ). The first part, τ , denotes a stopping rule,
mapping each pair (n,Σn) into a decision of whether to stop the trial or continue taking
samples. The second part denotes the treatment decision given that the trial is stopped,
with Dτ = 1 corresponding to treatment A and Dτ = −1 corresponding to treatment
B. Using τ as a stopping rule, the total number of superior and inferior treatments is
τ/2 each in the trial phase, so that the expected response is θτ for the trial patients.
For the post-trial patients, the expected response is (N − τ)(θ+Dτµ). Hence, the total
expected response for a given µ over the patient horizon is Nθ+µEµ [(N − τ)Dτ ], where
Eµ denotes the expectation given a specific value of µ. Note that the leading term Nθ
can be ignored when optimising, since it does not depend on the decision rule. Therefore,
for a given value of µ and a rule (τ,Dτ ), we are faced with the expected utility
µEµ [(N − τ)Dτ ] . (1.1)
In principle, having specified a prior distribution for µ, it is possible to solve the resulting
optimal stopping problem by straightforward backward induction. However, even for
moderate values of N the required computations will be quite heavy. Noting that Σn is
a Gaussian random walk with E [Σn] = nµ and Var(Σn) = nσ2, we can naturally extend
the discrete time process and instead consider a Brownian motion (Σt)t∈[0,N ] with drift
µ, volatility σ and filtration (Ft)t∈[0,N ]. Maximisation of the expected value of (1.1),
with respect to a prior for µ, then leads to a Markovian optimal stopping problem that
can be solved using the free-boundary approach.
An overview of related literature is given in the following subsection. We begin our
analysis by presenting a framework for solving the problem for a general prior distribution
in Section 2. Using Girsanov’s transform, it is shown that the problem is equivalent to
an ordinary Markovian optimal stopping problem. A standardising transformation then
leads to a problem which is independent of the parameters σ and N . A non-linear
integral equation defining the unique optimal stopping boundary in the special case of
a symmetric prior distribution is derived. The special case of conjugate normal priors
is studied in Section 3. It turns out that one really only needs to solve a single optimal
stopping problem in order to obtain the optimal stopping boundary for any prior in
this class. Section 4 takes a maximin approach to the problem and shows that this
is equivalent to placing a symmetric two-point prior on the unknown effect parameter.
Numerical schemes available for solving the integral equations are discussed in Section 5.
The first of our extensions to Anscombe’s problem is treated in Section 6. It is shown that
this model leads to asymmetric stopping boundaries which, as for the original problem,
can be described using integral equations. Certain asymptotic results first derived by
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Chernoff and Petkau (1981), adapted to this asymmetric case, are presented in Section
6.1. The other extension, with a random patient horizon, is presented in Section 7.
A discussion of the practical applicability of Anscombe’s model is given in Section 8,
where we also consider its implications for the regulation of clinical trials. Limitations
and possible further extensions of the model are also considered.
1.1. Related literature
One of the first major results in what would become the subject area of sequential
analysis was obtained by Wald (Wald, 1945; Wald and Wolfowitz, 1948). Essentially, the
classical Neyman-Pearson approach for constructing a statistical test of a null hypothesis
H0 against a single alternative H1 consists of selecting the non-sequential test with
the minimum sample size required to achieve a certain type II error from a class of
tests in which all members have the same type I error. Wald showed that a reduction
in the expected sample size could be achieved by allowing for sequential analysis of
the data. In particular, he demonstrated the construction of a decision rule called
the sequential probability ratio test (SPRT), which minimises the expected sample size
among all sequential rules satisfying fixed requirements on the type I and type II errors.
Wald’s SPRT is for all practical purposes the most efficient sequential test when both
H0 and H1 are simple hypotheses, that is, when they both consist of single points in
the parameter space. However, the fully Bayesian decision-theoretic perspective calls
for a more flexible methodology. Instead of single point hypotheses, one would like to
be able to specify a prior distribution on the whole of the parameter space. Further,
minimisation of expected sample size under type I and type II error restrictions may
not be the appropriate objective when selecting the decision rule. Instead, the decision-
maker would typically want to find the optimal rule with respect to a utility function
that captures all the gains and costs involved with each possible sequence of decisions.
A large part of the early methodology for solving optimal stopping problems using
the free-boundary approach was developed by Chernoff in a series of publications during
the 1960s (Chernoff, 1961; Breakwell and Chernoff, 1964; Chernoff, 1965). The problem
studied in these papers is different from the one treated here. It involves the sequential
testing of whether the mean of a normal distribution is positive or negative, given an
infinite time horizon and a fixed cost per unit of observation time. Various properties of
the optimal boundary for the problem studied in these papers are given. In particular,
asymptotic expansions as the observation time goes to 0 and infinity are derived. How-
ever, the optimal boundary is not characterised over the entire time horizon. In a more
recent publication by Zhitlukhin and Muravlev (2013), an integral equation is derived
for a transformed version of the optimal boundary. This equation can then be solved
numerically in order to obtain a full description.
The particular optimal stopping problem investigated in this paper was formulated
by Anscombe (1963). He aims to minimise expected regret rather than to maximise
an explicit expression for the total expected utility, but since he assumes that the re-
gret is proportional to the absolute value of the unknown, incremental effect size, the
resulting mathematical model is the same as ours. In (Chernoff and Petkau, 1981),
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the free-boundary methodology developed earlier was applied to the problem proposed
by Anscombe. After making a standardising transformation, they derive (numerically)
the optimal procedure in the case of a normal conjugate prior on the unknown incre-
mental efficacy and compare its performance with the approximate solution suggested
by Anscombe and another alternative suggested by Begg and Mehta (1979). They also
characterise the asymptotic behaviour of the optimal stopping boundary for small sample
sizes, and provide a proof in the appendix of the paper. This proof has been of particular
value to us when deriving corresponding asymptotics for the asymmetric generalisation
of Anscombe’s problem in which treatment allocation may be unbalanced during the
trial phase.
A common criticism often raised in connection with Anscombe’s model is that it
does not reflect ethical considerations enough. This was a motivation for extending the
model by introducing ethical costs (Chernoff and Petkau, 1985). Petkau (1987) solved
the continuous time problem with a normal prior under the constraint that the trial
must stop before reaching a fixed fraction of the horizon N . In (Petkau, 2003), optimal
group sequential designs for Anscombe’s model are derived for both the truncated and
original version of the problem.
A recent contribution by Stallard et al. (2017) solves the problem of sample size
optimisation when comparing two treatments in a non-sequential trial. In contrast to
the normal response and specific gain function assumed in Anscombe’s model, their
framework allows for response distributions of general exponential family form depending
on a single parameter. Further, arbitrary continuous gain functions of the parameter
may be specified. The main result obtained is that the optimal fixed sample sizes are
O(
√
N) as N →∞.
Although this literature review is by necessity quite selective, it shows that there
has been a continuous interest in Anscombe’s problem in the statistical community
throughout the decades since it was first introduced. However, the modern theory and
results surrounding the free-boundary approach to solving optimal stopping problems
that we employ here is not tied to this specific setting but has a much wider applicability.
A comprehensive reference work is the monograph by Peškir and Shiryaev (2006), which
applies the theory to a range of different problems in stochastic analysis, statistics and
finance. For a survey covering the origins of the modern approach and more recent
applications of the theory to problems in different areas, see the article by Lai and Lim
(2005). In addition to discussing applications to problems of sequential analysis and
Bayes optimisation of clinical trials, Lai and Lim also review the work done by Bather
and Chernoff on singular stochastic control in the 1960’s, and their own contributions
to problems in option pricing hedging in the presence of transaction costs.
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2. Bayesian formulation with general prior distributions
Given a prior distribution ν for µ in formula (1.1), the problem to solve is
sup
0≤τ≤N
Dτ∈{1,−1}
∫
µEµ [(N − τ)Dτ ] ν(dµ). (2.1)
We tackle this problem by first applying Girsanov’s transform (Øksendal, 2003, Theorem
8.6.4). Note that this is not a new approach in these kinds of problems, but corresponds
to standard methodology in filtering theory, see Bain and Crisan (2009, Section 3.3). For
example, Ekström and Vaicenavicius (2015) make use of essentially the same technique
when analysing a sequential testing problem of the drift of a Brownian motion. If a
change of measure is defined via
dP|Ft
dPµ|Ft
= exp
(
− µ
σ2
Σt+
µ2
2σ2 t
)
, (2.2)
then the process (Σt) is a Brownian motion with drift 0, volatility σ and starting value
Σ0 = 0 under the new measure P. Making use of this in problem (2.1) we obtain that
for each decision rule (τ,Dτ ),∫
µEµ [(N − τ)Dτ ] ν(dµ) =
∫
µE
[
exp
(
µ
σ2
Στ − µ
2
2σ2 τ
)
(N − τ)Dτ
]
ν(dµ) =
E
[∫
µexp
(
µ
σ2
Στ − µ
2
2σ2 τ
)
(N − τ)Dτ ν(dµ)
]
= E
[
hν(τ/σ2,Στ/σ2)(N − τ)Dτ
]
,
where hν(t,x)≡
∫
µexp
(
µx− µ
2
2 t
)
ν(dµ). (2.3)
For the problem to be nontrivial, we assume here and in the following that ν has finite
first moment, which guarantees that the function hν is well-defined for (t,x)∈ (0,N ]×R.
Let sgn(·) denote the function
sgn(x) =
{
1, x≥ 0,
−1, x < 0.
For a fixed stopping time τ , it is then clear from the calculation above that the expecta-
tion in problem (2.1) is maximised for D∗τ = sgn
(
hν(τ/σ2,Στ/σ2)
)
. To get the optimal
expected utility, it therefore remains to maximise the expectation
E
[
(N − τ)∣∣hν(τ/σ2,Στ/σ2)∣∣] .
Note that this is a standard Markovian stopping problem. We have now proved
Theorem 2.1. In the optimisation problem (2.1) with a prior ν, the optimal decision
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variable is given by D∗τ = sgn
(
hν(τ/σ2,Στ/σ2)
)
and the optimal stopping time τ∗ solves
sup
0≤τ≤N
E
[
(N − τ)∣∣hν(τ/σ2,Στ/σ2)∣∣] . (2.4)
In order to conveniently exploit the Markovian structure in optimal stopping problems
of type (2.4), the canonical first step is to extend the problem to general starting states
(t,x). In the present case, we do this by introducing a value function V (t,x) and a
reward function G(t,x) according to
V (t,x) = sup
t≤τ≤N
E(t,x) [G(τ,Στ )] , (2.5)
G(t,x) = (N − t)∣∣hν(t/σ2,x/σ2)∣∣. (2.6)
Here and in the following, E(t,x) denotes the expectation given that the process is started
in point (t,x). The original problem, as formulated in (2.4), then corresponds to the
starting state (t,x) = (0,0).
2.1. A standardising transformation
It is convenient to make a time-space transformation in the problem defined by equations
(2.5) and (2.6) before attempting to solve it. Define δ ≡ µ
√
N
σ . The prior distribution ν
for µ then corresponds to a prior distribution ξ for δ satisfying ξ(E) = ν
(
σ√
N
E
)
for any
measurable subset E of the real line. Further, define
r = t
N
, y = x√
Nσ2
, Sr =
ΣNr√
Nσ2
.
By Brownian scaling, this makes the new process (Sr) a standard Brownian motion. The
function hν can now be rewritten as
hν(τ/σ2,Στ/σ2) =
∫
µexp
(
µ
σ2
Στ − µ
2
2σ2 τ
)
ν(dµ) =
∫
µexp
(
µ
σ
√
NSτ/N −
µ2
2σ2 τ
)
ν(dµ)
= σ√
N
∫
δ exp
(
δSτ/N −
δ2
2 (τ/N)
)
ξ(dδ) = σ√
N
hξ
(
τ/N,Sτ/N
)
.
It follows that
G(τ,Στ ) = σ
√
N(1− τ/N)
∣∣∣hξ (τ/N,Sτ/N)∣∣∣ .
Since the constant factor σ
√
N does not affect the optimal solution, the original problem
is thus reduced to the standardised form
V˜ (r,y) = sup
r≤ρ≤1
E(r,y)
[
G˜(ρ,Sρ)
]
, (2.7)
G˜(r,y) = (1− r)|hξ(r,y)|. (2.8)
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2.2. Symmetric priors
Having shown how Anscombe’s problem can be formulated as a standard Markovian
optimal stopping problem for general priors, we now turn to the question of how to obtain
solutions using the method of integral equations. Assuming sufficient regularity, these
solutions can be expressed as boundaries enclosing a continuation region for the observed
process. In general, the continuation region for the process need not be symmetric if
priors of a general form are allowed. In order to simplify the presentation of the central
results, we restrict the theoretical development in this section to the case of symmetric
priors, satisfying ξ(dδ) = ξ(−dδ). In this case, it is immediately seen that
hξ(r,y) = 2
∫ ∞
0
δ exp
(
−δ
2
2 r
)
sinh(δy) ξ(dδ). (2.9)
Thus, hξ(r, ·) becomes an odd function for fixed r. We therefore obtain
Corollary 2.2. In the optimisation problem defined by equations (2.7) and (2.8) with
a symmetric prior ξ, the optimal decision variable is given by D∗ρ = sgn(Sρ) and the
optimal stopping time ρ∗ solves the Markovian optimal stopping problem
sup
0≤ρ≤1
E
[
(1−ρ)hξ (ρ, |Sρ|)
]
.
By the general theory of optimal stopping problems for Markov processes, the optimal
stopping time may be expressed as
ρ∗ = inf{r : (r,Sr) ∈ S}, where S≡ {(r,y) : V˜ (r,y) = G˜(r,y)}.
Since the prior ξ is symmetric, it is clear that the optimal stopping set S must also be
symmetric. Now, our interest here is not in providing the precise technical conditions
under which a solution may be obtained via the free-boundary method and integral
equations. Detailed discussions are provided for a long list of similar problems elsewhere
in the literature, see Peškir and Shiryaev (2006) for an overview or Ekström and Vaice-
navicius (2015) for a more recent result. Rather, we wish to illustrate how the general
approach may be used to solve Anscombe’s classical problem and various extensions of
it. Therefore, it will be assumed in what follows that the prior ξ is sufficiently regular
to imply the existence of a continuous boundary function bS(r) such that the stopping
time ρ∗ = inf{r : |Sr| ≥ bS(r)}∧1 is optimal. Following the arguments of Pedersen and
Peškir (2002), an application of a generalised version of Itô’s formula then — under weak
assumptions — leads to the following integral equation for bS :
E(r,bS(r))
[
G˜(1,S1)
]
= G˜(r,bS(r))
+
∫ 1
r
E(r,bS(r))
[(
∂
∂r
+ 12
∂2
∂2y
)
G˜(u,Su)I(|Su| ≥ bS(u))
]
du, 0≤ r ≤ 1. (2.10)
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Since G˜ vanishes when r= 1, the left hand side of equation (2.10) is zero. The differential
operator applied to G˜ gives(
∂
∂r
+ 12
∂2
∂2y
)
G˜(r,y) =−hξ(r, |y|).
Hence, the integral equation is reduced to
(1− r)hξ(r,bS(r)) =
∫ 1
r
E(r,bS(r))
[
hξ(u, |Su|)I(|Su| ≥ bS(u))
]
du, 0≤ r ≤ 1. (2.11)
The expectation in equation (2.11) can be rewritten in terms of the standard normal
distribution function Φ as∫ ∞
−∞
δe−δ
2r/2
{
eδbS(r)Φ
(
A+δ
)
+e−δbS(r)Φ
(
A−δ
)}
ξ(dδ), (2.12)
where
A±δ ≡
δ(u− r)− bS(u)± bS(r)√
u− r .
A result by Pedersen and Peškir (2002, Theorem 2.1), slightly adapted to our setting,
leads to the following uniqueness result for the solution to equation (2.11):
Theorem 2.3. Suppose ξ is a symmetric measure and sufficiently regular to imply
the existence of a continuous bS(r) satisyfing equation (2.11) and making inf{r : |Sr| ≥
bS(r)}∧1 an optimal stopping time. Then bS(r) is the unique solution to equation (2.11)
in the class of all continuous boundaries.
The proof of Theorem 2.3 is given in Appendix A.
3. Conjugate normal priors
We now illustrate how Theorem 2.1 (after the standardising transformation) can be
used to obtain the optimal boundary for a normal prior, which is conjugate to the
Brownian motion model assumed for the sum process (Sr). Given a prior for µ of the
form ν =N (v0,σ20), the corresponding prior for δ after the transformation δ = µ
√
N
σ is
ξ =N
(
m0 ≡ v0
√
N
σ
,
N
σ2
σ20
)
.
A convenient parameterisation of the prior variance is now obtained by letting n0 be the
number of ’prior observations’ and defining σ20 = σ2/n0. Letting r0 be the ratio n0/N ,
it follows that ξ =N (m0,1/r0).
Up to a constant that doesn’t play a role for the optimisation, elementary calculus
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yields that
hξ(r,y) =mr(y)β(r,y), mr(y)≡ m0r0 +y
r0 + r
, β(r,y)≡
exp
(
1
2mr(y)2(r0 + r)
)
√
r0 + r
.
Here, mr(y) is the mean of the posterior distribution for δ at time r given that Sr = y.
The important observation for treating normal priors with arbitrary parameters at the
same time is that the function β is a positive time-space harmonic function in the sense
that the process (β(r,Sr)) is a martingale. This implies that β can be used to perform
a change of measure using the h-transform (Borodin and Salminen, 2002, II.31). Under
the new measure P˜ with corresponding expectation E˜ we have
E
[
(1−ρ)∣∣hξ(ρ,Sρ)∣∣]= E˜[(1−ρ)|Mρ|],
where Mr ≡mr(Sr) is the posterior mean process. Using standard facts about the h-
transform, it is immediately checked that (Mr) is a diffusion process with zero drift
starting in (r,y) = (0,m0). Whenever we work with this process, we assume that we
work under the probability measure P˜. As we do not expect it to cause any confusion,
we leave out the tilde in the following in order to simplify the exposition.
Every prior that is conjugate normal is defined by the two parameters m0 and r0.
At a first glance, it would therefore seem reasonable to expect that one would have
to solve a distinct optimal stopping problem for each such pair (m0, r0). However, as
we will now demonstrate, by using a certain time transformation, the optimal stopping
problem for (Mr) may be transformed into a new one for which the optimal boundary is
independent of the prior parameters. The solution for a particular pair (m0, r0) can then
be recovered by a simple transformation of the optimal boundary for the standardised
problem. Specifically, introduce a new time s via the transformation
s=−r0 + 1
r0 + r
⇐⇒ r =−
(
r0 +
r0 + 1
s
)
, (3.1)
implying that r ∈ [0,1] corresponds to s ∈
[
−1− r−10 ,−1
]
. Applying this transformation
to the reward function obtained after the h-transform gives
(1− r)|Mr|=
(
1 +
(
r0 +
r0 + 1
s
))
|Mr(s)|=
√
r0 + 1
(
1 +s−1
)∣∣∣√r0 + 1Mr(s)∣∣∣ .
The time change is chosen so that the processWs≡
√
r0 + 1Mr(s) is a standard Brownian
motion (see, e.g., Øksendal (2003, Corollary 8.5.3)). Since a constant factor of
√
r0 + 1
does not affect the optimal stopping time, the standardised problem for the new time s
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is
Vˆ (s,y) = sup
s≤ζ≤−1
E(s,y)
[
Gˆ(ζ,Wζ)
]
, (3.2)
Gˆ(s,y) =
(
1 +s−1
)
|y|. (3.3)
Suppose now that we have solved the transformed problem and obtained a stopping
boundary c(s)≥ 0 for s≤−1. Then, going back to the original time r, it will be optimal
to stop if
|Ws(r)| ≥ c(s(r)) ⇐⇒
√
r0 + 1 |Mr| ≥ c(s(r)) ⇐⇒ |Mr| ≥
c
(
− r0+1r0+r
)
√
r0 + 1
.
Therefore, the optimal boundary for the posterior mean process is symmetric, with the
part in the positive half-plane given by
bM (r) =
c
(
− r0+1r0+r
)
√
r0 + 1
. (3.4)
The optimal boundary for the sum process is only symmetric if the prior mean is zero. Let
b+S (r) and b
−
S (r) denote the upper and lower parts of the boundary, respectively, which
together enclose the continuation region for the process. SinceMr = (m0r0+Sr)/(r0+r),
Mr ≥ bM (r) ⇐⇒ Sr ≥−m0r0 + (r0 + r)bM (r),
Mr ≤−bM (r) ⇐⇒ Sr ≤−m0r0− (r0 + r)bM (r).
Hence, b+S (r) and b
−
S (r) are given by
b±S (r) =−m0r0±
(r0 + r)c
(
− r0+1r0+r
)
√
r0 + 1
. (3.5)
Another boundary of interest for us is the one associated with the one-sided p-value
process (pr), which is defined as pr ≡ 1−Φ(Sr/
√
r). Its form follows immediately from
the definition of (pr) and equation (3.5),
bp(r) = 1−Φ
−m0r0 + (r0 + r)c
(
− r0+1r0+r
)
√
r0 + 1
/√r
 . (3.6)
Note the directional change implied by this transformation, i.e., stopping as soon as
Sr ≥ b+S (r) is equivalent to stopping as soon as pr ≤ bp(r). There are two main reasons to
study this boundary. Firstly, in the limit r0→ 0, bp(r) coincides with a certain boundary
for which Chernoff and Petkau (1981) have obtained asymptotic results (see Section 6.1).
Secondly, p-values are often used to support a regulator’s decision of whether or not to
approve a new medical treatment for marketing. Arguing as in Section 2.2, we obtain
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Theorem 3.1. For a conjugate normal prior defined by the pair (m0, r0), the optimal
stopping boundaries for the sum process and the p-value process may be expressed in
terms of a single boundary c(s) via equations (3.5) and (3.6). Here, c(s) is the unique
solution to the integral equation(
1 +s−1
)
c(s) =
∫ −1
s
u−2E(s,c(s))
[
|Wu|I
(|Wu| ≥ c(u))]du, s≤−1, (3.7)
in the class of all continuous boundaries.
The expectation in the integrand above can be found explicitly in terms of the standard
normal density function φ and distribution function Φ. Such a computation gives
E(s,c(s))
[
|Wu|I
(|Wu| ≥ c(u))]=√u−s(φ(c(u)− c(s)√
u−s
)
+φ
(−c(u)− c(s)√
u−s
))
+ c(s)
(
1−Φ
(
c(u)− c(s)√
u−s
)
−Φ
(−c(u)− c(s)√
u−s
))
.
Figure 1 shows b+S (r) and bp(r) for the three symmetric conjugate normal priors defined
by (m0, r0) = (0,0),(0,0.1),(0,1).
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Figure 1. b+S (r) and bp(r) for symmetric normal priors.
4. A maximin formulation
In this section, we will briefly consider an alternative criterion characterising the optimal
stopping time. Instead of maximising (1.1) with respect to a Bayesian prior, we adopt
a maximin approach and search for the stopping time which maximises the expected
response for the worst case scenario. The problem will be treated in the setting obtained
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after the standardising transformation described in Section 2.1. It is assumed that
the unknown parameter δ has a known absolute value δ0 > 0, but that we are unsure
about the sign. Motivated by this symmetry, we decide for treatment A if Sρ > 0 and
for treatment B otherwise, i.e., we take Dρ = sgn(Sρ). Noting that the multiplicative
constant δ0 appears in front of the expectation for both positive and negative δ, we are
then faced with the maximin problem
sup
0≤ρ≤1
min
(
Eδ0
[
(1−ρ)sgn(Sρ)
]
,−E−δ0[(1−ρ)sgn(Sρ)]) . (4.1)
4.1. Reduction to an ordinary stopping problem
The optimal stopping problem (4.1) does not fall into the setting of worst-case-type
optimal stopping problems with unknown drift recently studied by Riedel (2009); Cheng
and Riedel (2013), so that another approach is needed. As in Section 2, we apply
Girsanov’s transform via the change of measure transformations
dP|Fr
dPδ0 |Fr
= exp
(
−δ0Sr + δ
2
0
2 r
)
,
dP|Fr
dP−δ0 |Fr
= exp
(
δ0Sr +
δ20
2 r
)
.
This implies that the two expectations may be written as
E+(ρ)≡ Eδ0 [(1−ρ)sgn(Sρ)] = E
[
(1−ρ)sgn(Sρ)exp
(
δ0Sρ− δ
2
0
2 ρ
)]
,
E−(ρ)≡−E−δ0 [(1−ρ)sgn(Sρ)] =−E
[
(1−ρ)sgn(Sρ)exp
(
−δ0Sρ− δ
2
0
2 ρ
)]
,
where the process (Sr) is a Brownian motion with drift 0 and volatility 1 under the new
measure P. Next, define a new expectation E¯(ρ) as
E¯(ρ)≡ E
+(ρ) +E−(ρ)
2 = E
[
(1−ρ)exp
(
−δ
2
0
2 ρ
)
sinh(δ0|Sρ|)
]
.
Since, trivially, min
(
E+(ρ),E−(ρ)
)≤ E¯(ρ), it follows that
sup
ρ
min
(
E+(ρ),E−(ρ)
)
≤ sup
ρ
E¯(ρ). (4.2)
Now, supρ E¯(ρ) is a Markovian optimal stopping problem that can be solved using stan-
dard techniques, resulting in an optimal stopping time ρ∗ that may be expressed in terms
of a symmetric boundary for the process S. Due to the symmetry of the situation, it is
clear here that E+(ρ∗) = E−(ρ∗), implying
min
(
E+(ρ∗),E−(ρ∗)
)
= E¯(ρ∗) = sup
0≤ρ≤1
E¯(ρ).
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Keeping the inequality (4.2) in mind, this proves that the stopping time ρ∗ is the max-
imiser for problem (4.1), which leads to
Theorem 4.1. There exists a maximiser ρ∗ for problem (4.1) and ρ∗ is the optimal
stopping time for the standard Markovian stopping problem
sup
0≤ρ≤1
E
[
(1−ρ)exp
(
−δ
2
0
2 ρ
)
sinh(δ0|Sρ|)
]
. (4.3)
The auxiliary optimal stopping problem (4.3) used for the solution of the maximin
problem (4.1) can be seen as a Bayesian formulation of the decision problem defined by
equation (2.7) and (2.8) with a symmetric, two-point prior. Indeed, letting ξ be defined
as ξ({δ0}) = ξ({−δ0}) = 1/2, formula (2.9) immediately implies that
hξ(ρ, |Sρ|) = δ0 exp
(
−δ
2
0
2 ρ
)
sinh(δ0|Sρ|) .
Figure 2 shows b+S (r) and bp(r) for the three symmetric two-point priors defined by
δ0 = 0.1,1,10.
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Figure 2. b+S (r) and bp(r) for the two-point priors defined by δ0 = 0.1,1,10.
5. Numerical solution
This section describes the numerical method used for solving the optimal stopping prob-
lems treated in this paper, which is based on discretising the integral equation for the
optimal boundary and then solving it backwards in time. Some alternative approaches
to obtain solutions are also briefly discussed. Since numerical issues are not the main
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focus of this paper, no exhaustive comparison of different procedures based on efficiency
or accuracy has been done. The only note we make here is that the integral equation
approach is certainly a viable one, and that it provides approximations of reasonable
accuracy given the time required to run the algorithm. Moreover, it is straightforward
to implement a simple version of the algorithm.
5.1. Integral equation approach
Equation (2.11) for the boundary of the standardised problem can be viewed as an
instance of a Volterra integral equation of the second kind,
g(r,bS(r)) =
∫ 1
r
K (u,r,bS(u), bS(r)) du, 0≤ r ≤ 1, (5.1)
where the functions g and K are defined as
g(r,y)≡ (1− r)hξ(r,y),
K(u,r,z,y)≡ E(r,y)
[
hξ(u, |Su|)I(|Su| ≥ z)
]
.
The numerical method uses the trapezoidal rule in order to replace the integral in
equation (5.1) by a sum. Given a grid of k time points 1 = r1 > r2 > .. . > rk, letting
bi = bS(ri), the discretised version of equation (5.1) reads
g(ri, bi)≈
i−1∑
j=1
(rj− rj+1)
(
K (rj+1, ri, bj+1, bi) +K (rj , ri, bj , bi)
2
)
, 2≤ i≤ k.
For i= 2, the above leads to the algebraic equation
g(r2, b2) = (r1− r2)
(
K (r2, r2, b2, b2) +K (r1, r2, b1, b2)
2
)
for b2, which may be solved using some appropriate numerical procedure. The remaining
bi are then found by solving algebraic equations containing the previously computed
values b1, . . . , bi−1.
Note that the algebraic equation will include the term K (ri, ri, bi, bi) at each step,
which can not be computed directly. Such terms are instead computed by replacing
r by ri in limu↓rK(u,r,bS(u), bS(r)). Under the assumption that the function bS(r) is
differentiable, the form of the limit follows from equation (2.12):
lim
u↓r
K(u,r,bS(u), bS(r)) = lim
u↓r
∫ ∞
−∞
δe−δ
2r/2
{
eδbS(r)Φ
(
A+δ
)
+e−δbS(r)Φ
(
A−δ
)}
ξ(dδ)
=
∫ ∞
−∞
δe−δ
2r/2
{
eδbS(r) lim
u↓r
Φ
(
A+δ
)
+e−δbS(r) lim
u↓r
Φ
(
A−δ
)}
ξ(dδ)
= 12
∫ ∞
−∞
δe−δ
2r/2eδbS(r) ξ(dδ).
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5.2. Fixed-point equation approach
Another approach for obtaining a numerical approximation of the optimal boundary is
to reformulate equation (5.1) as a fixed point equation. Since
g(r,bS(r)) =
∫ 1
r
K (u,r,bS(u), bS(r)) du ⇐⇒
bS(r) = bS(r) +
∫ 1
r
K (u,r,bS(u), bS(r)) du−g(r,bS(r)),
if an operator Q is defined as
(QbS)(r) = bS(r) +
∫ 1
r
K (u,r,bS(u), bS(r)) du−g(r,bS(r)), (5.2)
then bS solves equation (5.1) if and only if it is a fixed point for Q, i.e., if and only if it
solves
bS(r) = (QbS)(r), 0≤ r ≤ 1. (5.3)
Operationally, the corresponding numerical algorithm may start with a piecewise linear
function b0S defined on a grid r1 > .. . > rk as b0S,i = b0S(ri) = 0. A new piecewise linear
function b1S is then computed by applying the operator Q to b0S , that is, b1S is defined at
the grid points as b1S,i = (Qb0S)(ri). This process is then repeated, producing a sequence
of piecewise linear functions b0S , b1S , . . .. For many of the kernel functions considered in
this paper, approximate convergence is obtained after a reasonable number of iterations.
However, we found that the trapezoidal method tends to be more computationally effi-
cient.
5.3. Value function approach
Chernoff and Petkau (1986) describe an alternative method for computing numerical
approximations for optimal stopping boundaries. First, a finite sequence of time points
r1 > .. . > rk is chosen. For simplicity, assume this grid to be uniform, with distance ∆r
between each point. Let V denote the value function for this discrete problem. Since V
corresponds to the optimal decision rule, the backward induction criterion implies that
V (ri,y) = max
(
G(ri,y),E
[
V
(
ri−1,y+Z
√
∆r
)])
, (5.4)
where Z ∼N (0,1). Using this equation, it is possible to start at the largest time r1 and
compute approximations of V (ri, ·) in steps as i= 2, . . . ,k.
The main problem with this approach is that the expectation, taken with respect to a
normal distribution, may be too time consuming to evaluate when the time grid is fine
enough for the desired accuracy. Hence, another approximation is warranted, and the
one suggested by Chernoff and Petkau (1986) consists of replacing Z with a symmetric
Bernoulli distributed random variable Z˜ taking on the values ±√∆r. Equation (5.4)
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then becomes
V (ri,y) = max
(
G(ri,y),
1
2
(
V (ri−1,y+
√
∆r) +V (ri−1,y−
√
∆r)
))
. (5.5)
A possible choice for the grid is{(
r1− (i−1)
√
∆r,±j
√
∆r
)
: 1≤ i≤ k,j ≥ 0
}
.
The continuation and stopping regions can then be found by comparing the computed
V with the reward function G in each grid point.1
The approach described in this subsection yields the optimal boundary after first
computing the value function. In contrast, the method used to produce the plots included
in this paper is based on deriving an integral equation for the boundary and then seeking
an approximate solution to this equation. In a sense, the latter approach is more direct,
since the value function is not explicitly involved. However, sometimes the value function
itself is of interest, and a minimal implementation of a solver for the integral equation
will not yield the value function without additional computations.
6. A related asymmetric problem
In practice, it is unlikely that all patients afflicted by a given disease are available for
inclusion in the trial. Even if every patient was asked to participate, some may choose
not to. Typically, these patients will still receive some treatment while the trial is in
progress. This motivates us to consider a generalised form of Anscombe’s problem, and
it will be seen that its solution consists of an asymmetric boundary for the optimal
stopping region.
As for the original model, let N be the maximum number of patients that may be
included in the trial. For each patient included, we will denote by q the number of
patients that, for whatever reason, will not participate. Hence, the total number of
patients considered is (q+ 1)N . It is assumed that the non-participants are given the
standard treatment B during the trial. The probabilistic model is exactly as before and
the objective is now to choose the stopping time τ and the terminal treatment decision
Dτ so as to maximise the expected utility (i.e., the aggregated treatment response)
over all (q+ 1)N patients. Since (q+ 1)(N − τ) patients are treated after the trial, the
expected utility given µ for the post-trial patients is µEµ [(q+ 1)(N − τ)Dτ ]. In addition,
since qτ patients are treated with B in the trial phase, we have to add an expected utility
of −µEµ [qτ ] and so obtain a total expected utility given µ of
µEµ [(q+ 1)(N − τ)Dτ − qτ ] . (6.1)
Placing a prior ν on µ and arguing as in Section 2, we are faced with the problem of
1This is known as the binomial tree method in the literature.
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maximising∫
µEµ [(q+ 1)(N − τ)Dτ − qτ ] ν(dµ) = E
[
hν(τ/σ2,Στ/σ2)
(
(q+ 1)(N − τ)Dτ − qτ
)]
.
As before, D∗τ = sgn
(
hν(τ/σ2,Στ/σ2)
)
maximises the expectation for each fixed τ , so
that the problem is reduced to
sup
0≤τ≤N
E
[∣∣hν(τ/σ2,Στ/σ2)∣∣(q+ 1)(N − τ)−hν(τ/σ2,Sτ/σ2)qτ] .
In order to bring the above into a form that more closely resembles the separation of
the time and state dependence into two factors (as for the original problem), we add
to the above a term with conditional expectation independent of the stopping time.
More precisely, as adding the martingale
(
qNhν(t/σ2,Σt/σ2)
)
t∈[0,N ] does not change the
optimal stopping time, the problem is equivalent to that of maximising
E
[∣∣hν(τ/σ2,Στ/σ2)∣∣(q+ 1)(N − τ)−hν(τ/σ2,Στ/σ2)qτ + qNhν(τ/σ2,Στ/σ2)]=
E
[
(N − τ)
(∣∣hν(τ/σ2,Στ/σ2)∣∣+ 2qhν(τ/σ2,Στ/σ2)+)] ,
where h+ν denotes the positive part of hν . We have now proved
Theorem 6.1. For the problem of maximising the expected value of (6.1) with respect
to a prior ν on µ, the optimal decision variable is given by D∗τ = sgn
(
hν(τ/σ2,Στ/σ2)
)
and the optimal stopping time τ∗ solves the Markovian optimal stopping problem
sup
0≤τ≤N
E
[
(N − τ)
(∣∣hν(τ/σ2,Στ/σ2)∣∣+ 2qhν(τ/σ2,Στ/σ2)+)] . (6.2)
Application of the standardising time-space transformation described in Section 2.1
now leads to the problem
sup
0≤ρ≤1
E
[
(1−ρ)
(∣∣hξ(ρ,Sρ)∣∣+ 2qhξ(ρ,Sρ)+)] , (6.3)
where, as before, ξ is the prior on δ induced by the relation δ= µ
√
N
σ . As expected, when
q = 0, problem (6.3) is reduced to the original symmetric problem defined by equations
(2.7) and (2.8). It is interesting to consider the effect upon the solution when q→∞,
corresponding to the case in which a large number of patients will be given the standard
treatment in parallel with the trial. For example, this would be the case if the targeted
disease is relatively common. Since problem (6.3) is equivalent to the one obtained when
dividing through by 2q, we obtain the following (non-degenerated) problem in the limit
q→∞:
sup
0≤ρ≤1
E
[
(1−ρ)hξ(ρ,Sρ)+
]
. (6.4)
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Figure 3 shows b+S (r) and bp(r) when an uninformative normal conjugate prior is used
for q = 0,1,5,∞.
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Figure 3. b+S (r) and bp(r) for the asymmetric problem. The prior corresponds to the
limit case of a conjugate normal one, with (m0, r0) = (0,0).
6.1. Asymptotic results when r0 and r are small
Consider the case of a normal conjugate prior for δ. Recall that the time parameter r was
defined as the ratio r= n/N and that r0 was defined as n0/N , where n0 is the number of
virtual observations in the prior. In many cases, it seems reasonable to assume that the
total population size N is very large compared to n0, thus making r0 very small. In the
beginning of the trial, the optimal strategy is determined by the shape of the boundary
when r is small. Hence, the asymptotic behaviour of the boundaries when both r0 and
r are small is of particular interest for the implementation of the optimal procedure at
the beginning of the trial.
Optimal boundary asymptotics for Anscombe’s problem have previously been studied
by Chernoff and Petkau (1981). In the remaining part of this section, we will describe
how their derivation can be modified so as to also cover the asymmetric problem with
q > 0. Further, it will be shown how this result can be used to derive an approximate
expression for the optimal boundary of the p-value process. For the asymmetric problem,
the standardised optimal stopping problem is
Vˆ (s,y) = sup
s≤ζ≤−1
E(s,y)
[
Gˆ(ζ,Wζ)
]
,
Gˆ(s,y) =
(
1 +s−1
)(
|y|+ 2qy+
)
.
By equation (3.1), small values of r0 and r correspond to large negative values for s. As
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s→−∞, we obtain the approximation
Gˆ(s,y) =
(
1 +s−1
)(
|y|+ 2qy+
)
≈ Gˆ−∞(y)≡ |y|+ 2qy+.
This suggests that the value function Vˆ solving the problem may be approximated (as
s→−∞) with a solution to the equation
(
∂
∂s +
1
2
∂2
∂2y
)
Vˆ = 0 that is approximately equal
to Gˆ−∞(y). Setting z = y(−s)−1/2, such a function is given by
E
[
Gˆ−∞(W0) |Ws = y
]
= 2(−s)1/2ψq(z),
ψq(z)≡ φ(z)(1 + q) +z (Φ(z)(1 + q)−1/2) .
Note that E
[
Gˆ−∞(W0) |Ws
]
is a martingale when considered as a process in time s.
Hence, the optimal boundary may be found by solving the problem obtained by replacing
Gˆ with the modified reward function Gˆ0 = Gˆ(s,y)− 2(−s)1/2ψq(z). In this modified
reward, the major part of Gˆ(s,y) has been cancelled by the martingale. This facilitates
the matching of terms in the asymptotic expansion of the boundary. The remaining
steps of the derivation leading to the result below closely follows Chernoff and Petkau
(1981) and may be found in Appendix B.
Theorem 6.2. Let c+q (s) be the upper part of the optimal boundary for the standardised
version of the asymmetric problem with a normal conjugate prior. Then
c+q (s)∼
√−sΦ−1
(
1 +
(1 + 2q
1 + q
)
s−1
)
, s→−∞. (6.5)
The p-value process boundary is defined in terms of c+q (s) according to
bp(r,q) = 1−Φ
−m0r0 + (r0 + r)c+q
(
− r0+1r0+r
)
√
r0 + 1
/√r
 .
When both r0 and r are small, the result (6.5) therefore leads to the approximation
bp(r,q)≈ 1−Φ
−m0r0 +√r0 + rΦ−1
(
1−
(
1+2q
1+q
)(
r0+r
r0+1
))
√
r
 . (6.6)
The limit case of an uninformative prior corresponds to r0 = 0, which gives the simpler
form
bp(r,q)≈ 1−Φ
(
Φ−1
(
1−
(1 + 2q
1 + q
)
r
))
=
(1 + 2q
1 + q
)
r. (6.7)
7. Model with a random number of patients
One questionable assumption that has been made up to this point is that the patient
horizon N is known. In this section, we generalize the model by allowing N to be a
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(0,∞)-valued random variable with a finite mean. For example, N could be interpreted
as a time point at which a new (and highly competitive) drug arrives. At time N , we
assume the testing to stop immediately. In analogy with equation (1.1), for a given µ,
the expected utility reads as
µEµ
[
(N − τ)Dτ I{τ ≤N}
]
= µEµ
[
(N − τ)+Dτ
]
.
It is assumed that the random variable N is independent of the underlying process for
each given µ, so that we are faced with the expected utility
µEµ
[
(N − τ)+Dτ
]
= µEµ
[
fµ(τ)Dτ
]
, fµ(t)≡ Eµ
[
(N − t)+
]
.
By also making the further assumption that N is independent of the drift µ, it follows
that the value of fµ(t) is the same for all µ. This common value will be denoted by f(t).
Following the derivation of Section 2, the independence assumptions for N now leads to
Theorem 7.1. With an independent random time horizon N and a prior ν on µ, the
optimal decision variable is given by D∗τ = sgn
(
hν(τ/σ2,Στ/σ2)
)
and the optimal stopping
time τ∗ solves the Markovian optimal stopping problem
sup
0≤τ<∞
E
[
f(τ)
∣∣hν(τ/σ2,Στ/σ2)∣∣] . (7.1)
As done in Section 2.1, a standardising transformation can be performed also in the
case of a random N . For this, δ is defined using the expected value of N according to
δ = µ
√
E[N ]/σ, with the measure for δ denoted by ξ as before. The new time parameter
r is defined as the fraction of the expected total number of patients, r = t/E[N ] (giving
ρ= τ/E[N ]). This leads to the standardised optimal stopping problem
sup
0≤ρ<∞
E
[
f˜(ρ)
∣∣hξ(ρ,Sρ)∣∣] , f˜(r)≡ f(rE[N ])E[N ] ,
in which (Sr) is a Brownian motion with zero drift and unit volatility.
7.1. Some general properties of f˜ and some examples
It is immediately clear that f˜ is non-increasing in r, f˜(0) = 1 and limr→∞ f˜(r) = 0.
Under the assumption that N has a density piN , we also have
f ′(t) =
∫ ∞
0
∂
∂t
(
(u− t)+
)
piN (u)du=
∫ ∞
0
(−1)I(t < u)piN (u)du=−P(N > t) . (7.2)
Equation (7.2) implies that f˜ ′(r) = f ′(rE[N ]) = −P(N > rE[N ]) and, in particular,
f˜ ′(0) = −1. Since f is an integral of convex functions, it is also convex. Conversely,
given a convex, non-increasing function f on (0,∞), a distribution for N may be found
that generates f via the identity f ′(t) =−P(N > t).
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Example 7.2. Suppose N ∼ Exp(λ). Making use of the memoryless property of the
exponential distribution and that E[N ] = 1/λ,
f(t) = E [(N − t) |N > t]P(N > t) = e−λt/λ,
f˜(r) = f(rE[N ])
E[N ] = λf(r/λ) = e
−r.
Example 7.3. Suppose N ∼ Lomax(λ,ω) (Lomax, 1954), i.e.,
FN (u) = 1−
(
λ
λ+u
)ω
, u≥ 0, E[N ] = λ
ω−1 ,
where λ > 0 is a scale parameter, ω > 1 is a shape parameter and FN is the distribution
function of N . This distribution can be viewed as a Pareto Type I distribution, shifted
so that its support begins at zero. It has the property that N− t|N > t∼ Lomax(λ+ t,ω),
implying that
E[N − t |N > t] = λ+ t
ω−1 , P(N > t) =
(
λ
λ+ t
)ω
.
It follows that
f(t) = E [N − t |N > t]P(N > t) =
(
λω
ω−1
)
(λ+ t)1−ω ,
f˜(r) = f(rE[N ])
E[N ] =
(
ω−1
λ
)(
λω
ω−1
)(
λ+ r λ
ω−1
)1−ω
=
(
1 + r
ω−1
)1−ω
.
7.2. The maximin problem with an exponential number of patients
Considering the maximin problem from Section 4 with N ∼ Exp(λ), we are — keeping
Example 7.2 in mind — faced with the optimal stopping problem
sup
0≤ρ<∞
E
[
f˜(ρ)e−
δ20
2 ρ sinh(δ0|Sρ|)
]
= sup
0≤ρ<∞
E
e−
(
δ20
2 +1
)
ρ
sinh(δ0|Sρ|)
 .
This is a problem with infinite time horizon and discounting that can be solved with
standard techniques such as the change of measure technique (see Beibel and Lerche
(1997); Christensen and Irle (2011)). The differential equation
1
2y
′′ =
(
δ20
2 + 1
)
y
has the symmetric solution
y(x) = cosh(Cx), C ≡
√
δ20 + 2.
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This implies (see Beibel and Lerche (1997, Theorem 4)) that the optimal stopping time is
ρ∗1 = inf{r≥ 0 : |Sr| ≥ x∗1}, where x∗1 is the unique maximum point of sinh(δ0x)/cosh(Cx),
i.e., the unique positive solution of the algebraic equation
δ0 cosh(δ0x)cosh(Cx)−C sinh(δ0x)sinh(Cx) = 0.
Hence, the optimal boundary for the sum process is constant and completely determined
by the value of x∗1. Note also that the expectation of ρ∗ is E[ρ∗] = (x∗1)2 (Borodin and
Salminen, 2002).
Next, consider the asymmetric problem obtained by letting q→∞. We are then faced
with the optimal stopping problem
sup
0≤ρ<∞
E
e−
(
δ20
2 +1
)
ρ
sinh(δ0Sρ)+
 .
This problem is of one-sided type and we obtain — using Beibel and Lerche (1997,
Theorem 2) — that the optimal stopping time is given by ρ∗2 = inf{r ≥ 0 : Sr ≥ x∗2},
where x∗2 is the unique solution to
δ0 cosh(δ0x)exp(Cx)−C sinh(δ0x)exp(Cx) = 0.
Solving this equation gives
x∗2 =
ln
(√
δ20+2+δ0√
δ20+2−δ0
)
2δ0
=
ln
(√
δ20
2 + 1 +
δ0√
2
)
δ0
.
7.3. On the normal prior with a random time horizon
One advantage of the model extension discussed in this section is that it respects the
additional structure given by the normal distribution. Indeed, proceeding as in Section 3,
it can be seen that the standardised optimal stopping problem for the Brownian motion
(Ws) analogous to equations (3.2) and (3.3) is given by
Vˆ (s,y) = sup
s≤ζ<0
E(s,y)
[
G˜(ζ,Wζ)
]
,
Gˆ(s,y) = f˜
(
−r0− r0 + 1
s
)
|y|.
It is interesting to discuss the case in which N has a Lomax distribution. By Example
7.3,
f˜
(
−r0− r0 + 1
s
)
=
(
1 +
−r0− r0+1s
ω−1
)1−ω
=
(
ω−1− r0− r0+1s
ω−1
)1−ω
.
Recall that, in the case of a known N , r0 was defined as r0 = n0/N . For a Lomax-
distributed N , the definition is instead r0 = n0/E[N ] = n0(ω− 1)/λ. The special case
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of λ = n0 will be considered here, since this assumption allows us to obtain an explicit
functional form for the optimal stopping boundary of the standardised problem. Note
that this assumption implies that ω = r0 + 1. Using the expression for f˜ above, and
noting that the optimal boundary is not affected by a constant depending only on the
parameters, the optimal stopping problem to solve is
Vˆ (s,y) = sup
s≤ζ<0
E(s,y)
[
(−ζ)r0 |Wζ |
]
= sup
0≤ζ<−s
E
[
(−(s+ ζ))r0 |y+Wζ |
]
. (7.3)
The method now consists of transforming (7.3) into a solvable problem. Our approach
essentially follows the time-change method described by Peškir and Shiryaev (2006,
Section IV.10). Rewriting the argument of the expectation in (7.3) as
(−(s+ ζ))r0 |y+Wζ |= (−s)r0 (1− ζ/(−s))r0
√−s
∣∣∣∣ y√−s + 1√−sW(−s)(ζ/(−s))
∣∣∣∣ ,
setting ζ˜ = ζ/(−s) and noting that, by Brownian scaling, W˜s˜ = (1/
√−s)W(−s)s˜ is a
standard Brownian motion, (7.3) becomes
Vˆ (w˜) = sup
0≤ζ˜<1
Ew˜
[(
1− ζ˜
)r0 |W˜ζ˜ |] .
In this problem, the process (W˜s˜) starts at w˜= y√−s . The next step consists of performing
the transformation
Yˆs˜ =
1√
1− s˜ W˜s˜, s˜(sˆ) = 1−e
−2sˆ, Wˆsˆ = Yˆs˜(sˆ).
This makes (Wˆsˆ) an Ornstein-Uhlenbeck process with generator LWˆ = wˆ
∂
∂wˆ +
∂2
∂wˆ2 and
the stopping problem becomes
Vˆ (wˆ) = sup
0≤ζˆ<∞
Ewˆ
[
e−(2r0+1)ζˆ |Wˆζˆ |
]
, where wˆ = w˜ = y√−s.
Let M(·, ·, ·) denote the Kummer confluent hypergeometric function. It may then be
shown (Beibel and Lerche, 1997, Theorem 4) that the optimal stopping time in this
transformed problem is ζˆ∗ = inf{sˆ≥ 0 : |Wˆsˆ| ≥ wˆ∗(r0)}, where wˆ∗(r0) is the unique solu-
tion to the equation
2(r0 + 1)
M(r0 + 2,3/2, wˆ2/2)
M(r0 + 1,1/2, wˆ2/2) wˆ
2 = 1 + wˆ2. (7.4)
Transforming back to the original variable pair (s,Ws), it follows that the optimal bound-
ary for problem (7.3) has the form c(s) = wˆ∗(r0)
√−s.
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8. Discussion
8.1. On the use of Girsanov’s transformation
An early application of Girsanov’s transformation is central to our treatment of Anscombe’s
problem. The transformation allows for treating different priors in a common framework:
that of an optimal stopping problem for a Brownian motion with zero drift. In partic-
ular, we are by this route led to the observation that the optimal stopping boundary
for any normal, conjugate prior can be obtained by solving a single optimal stopping
problem. That this is possible was noted by Chernoff and Petkau (1981).
8.2. Model applications
In Anscombe’s formulation of the treatment selection problem, a number of simplifying
assumptions are intentionally made. Trial costs are ignored, the production costs of the
treatments once in usage are assumed to be the same and there are no costs involved
when switching from one treatment regime to another. Although it may be argued that
the basic model is not detailed enough to be directly applicable to practical trial design
problems, it can be extended for increased realism. For example, a recent contribution
by Pertile et al. (2014) makes use of Chernoff’s free-boundary approach to solve a model
taking treatment costs into account. The primary quantity of interest in their context is
not the incremental effect of A relative to B, but the net incremental monetary benefit,
which is obtained as the difference between the incremental effect (in monetary units) and
the incremental cost (on a per-patient level). Such an extended model is motivated by
the increasing focus on not only obtaining effective medications, but cost-effective ones.
Their analysis shows the flexibility of Chernoff’s approach and indicates an applicability
that far transcends Anscombe’s streamlined problem.
It is important to note that the perspective of the trial designer has an impact on
what kind of design that will be considered optimal. For publicly sponsored trials it
seems reasonable to assume that the main goal is to maximise the total public health.
Anscombe’s model, possibly extended with trial costs, would then seem appropriate. If
the sponsor is a pharmaceutical company, the goal is instead to find a design maximising
expected profit. Situations in which the profit is directly proportional to the aggregated
health benefit for the population, while certainly conceivable, would hardly be the most
common in practice.
In commercial drug development, a company with a new candidate drug plans a trial,
executes it and hands over the resulting data to a regulatory authority. Based on the trial
design and the resulting data, the regulator then either grants market approval or rejects
the new medication. In some cases, it might also ask the company to provide data from an
extended study before a final decision is made. The form of the decision rule used by the
regulator determines which medicines are approved for marketing and therefore impacts
public health. This raises the question of which particular rule to use. The canonical
procedure used by the FDA in the US has been to require significant statistical results
in two independent studies (FDA, 1998). For historical reasons, a significance level of
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5% is often used2, regardless of the prior information available before the trial, and also
without taking the sample size or the total population size into account.
The results obtained when analysing Anscombe’s model leads to an argument for using
a regulatory rule which is different from the classical one. In the interest of simplicity,
let us assume that the regulator’s decision is binary, i.e., either the medicine is approved
or it is not. Being presented with the trial data, the regulator can then map this data
to a point which will lie in the continuation or stopping region corresponding to the
optimal boundary for Anscombe’s model. If the point ends up in the stopping region,
then it would clearly be suboptimal from a public health perspective to reject the new
treatment. For if we imagine that the authority takes control of the trial procedure
and continues optimally, then it will realise that optimality dictates immediate stopping
(and distribution of the new medication). It is not as clear what the regulator should
do if the trial data yields a point in the continuation region. To continue would be
optimal if it could be done sequentially, but now a regulatory decision must be taken
directly. Sometimes it will be optimal to approve, and sometimes to reject. Hence, while
the argument does not lead to a complete specification of a replacement for the classical
rule, it does provide a motivation for using the optimal nominal p-value curve as a source
of lower bounds for significance level tests.
We will now use the approximation bp(r) = bp(r,q= 0)≈ r derived in Section 6.1, which
holds in limit case of an uninformative prior, to give a detailed example of the argument
in the preceding paragraph. Consider two different scenarios faced by a regulator:
1. Common disease and large trial: N1 = 108 and n1 = 103, giving r1 = n1N1 = 10
−5.
2. Rare disease and small trial: N2 = 105 and n2 = 102, giving r2 = n2N2 = 10
−3.
The rule bp(r) is compared with a model bcp(r) of the classical procedure in which sta-
tistical significance at level α is required in two independent trials if a new treatment
is to be accepted. Since we only consider one trial here, the independence assumption
implies that bcp(r) = α2. It is appropriate here to use one-sided significance levels and,
following tradition, we choose α = 0.025, giving bcp(r) = 0.000625. Note that there are
no sequential decisions by the regulator here, even though bp(r) was derived from such a
setting. Instead, the sponsor reports the observed value of the nominal p-value process
(pr) to the regulator (pr1 or pr2), which in turn compares this value with the adopted
curve (bp(r) or bcp(r)) and accepts the new treatment A if and only if the reported value
is below the curve.
Consider now the scenario of a common disease. The parameter values chosen implies
that bcp(r1) > bp(r1), so that the classical rule is less conservative than bp. Therefore, if
the new treatment is accepted when bp is used, it will also be accepted in the classical
regime. The situation is reversed in the scenario of a rare disease, because in this case
bcp(r2)< bp(r2). This means that there are possible outcomes of the trial which will result
in acceptance of A when bp is used but not when bcp is used.
2This particular value for the level goes back to a suggestion made by Fisher (1946).
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8.3. On the two extensions
8.3.1. The asymmetric problem
Assuming that q > 0 leads to asymmetric optimal stopping boundaries. The standard-
ised version of the problem in equation (6.3) can still be solved using the backwards
trapezoidal method described in Section 5. However, because of the asymmetry, it is
necessary to solve two coupled integral equations when applying the backwards proce-
dure producing the piecewise linear approximations to the boundaries. We omit the
details, since only minor modifications of the algorithm used when q = 0 are required.
It is easy to imagine practical applications in which the appropriate value for q would
be quite large. For example, consider a trial lasting one year and including one thousand
patients, aimed at comparing a new candidate treatment A with a standard alternative
B which is administered to one million patients outside the trial. This results in q= 1000.
It is interesting to note (see Figure 3) that the upper boundary for the acceptance of
the new treatment A rather rapidly approaches the optimal boundary corresponding to
the limit q→∞. One is led to conjecture that the optimal solution in this limit could
serve as an adequate approximation even if q is only moderately large.
In Section 8.2, we argued that a fixed significance level test is too conservative when
compared to the optimal boundary obtained for Anscombe’s original, symmetric problem
(with q = 0). Similarly, since b+S (r) decreases with increasing q for each fixed r, it follows
that the optimal boundary for the symmetric problem would also be too conservative in
many practical situations.
8.3.2. The random time horizon
When generalising the model to allow for a random N , it was assumed that
1. The horizon N is independent of the underlying process, i.e., the noise part of the
Brownian motion, given the drift µ,
2. the horizon N is independent of µ, and,
3. the only information obtained about N when observing the sum process continu-
ously up to time point t is that either N = t or N > t.
The first two assumptions are essential in order to arrive at the optimal stopping problem
in equation (7.1), in which the form of the function f(t) completely determines the effect
that the distribution ofN has on the optimal solution. Recall thatN is interpreted as the
time point at which both of the treatments A and B become obsolete and are replaced
by another treatment. Even though it seems quite reasonable to assume that the value
of N should therefore be determined by the properties of the treatment replacing A
and B, and not the observations made in a preceding trial, situations in which this
does not hold are still conceivable. For example, if it turns out that a new treatment
A is greatly superior to a standard alternative B, it may be argued that this should
make it harder to develop a superceding treatment which improves further upon A. The
density for N would change during the trial, shifting to the right as the estimate for
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µ grows. A generalisation of the random horizon model along these lines would be an
interesting topic for further research. If assumption 1 above is kept while 2 is dropped,
f(t) in Section 7 should be replaced by fµ(t), and hν in equation (7.1) would have to be
redefined so as to also include the dependence of N on µ.
Keeping the independence assumptions 1 and 2, it would also be interesting to con-
sider problems in which the distribution for N evolves in a more complicated way. For
instance, instead of assuming that a fixed distribution specified at time 0 is updated
by just conditioning on N > t, N could be defined as the jump time (from 1 to 0) of
a binary stochastic process adapted to some filtration that is independent of the trial
observations. The choice of this process would probably have to be done quite carefully
in order to make the problem tractable using available optimal stopping theory, but such
a generalisation might be a way to model more realistic belief dynamics about N .
8.4. Limitations and further research
One of the most basic assumptions in Anscombe’s model is that of normally distributed
responses. It is vital to assume this in order to arrive at the familiar frawework of
optimal stopping for a Brownian motion. However, because of the central limit theorem,
the model can be used to obtain at least approximately optimal boundaries in a wide
range of applications. Another assumption made is that the sample variance σ2 is known.
In practice, σ2 would quite likely need to be estimated as the response data accrues. It
would certainly be an interesting topic for further research to see just how much of
the framework that eventually remains if a prior is placed on σ2 and then updated
sequentially.
Introducing q as an additional parameter makes Anscombe’s model more flexible, but
also leads to the practical problem of estimating its value. Since the problem is similar
to that of estimating N , one is led to the idea of introducing a stochastic model also for
q. With sufficient independence assumptions, it might still be possible to proceed with
the analysis, although the authors have made no efforts in this direction.
A possibly contentious issue is the choice of the utility function to optimise. Anscombe’s
formulation leads to an aggregated utility that values each patient equally. A unit of
health is valued the same regardless of whether it benefits the first patient recruited to
the trial or patient number N . In particular, no discounting of future health benefits is
implemented, even though some form of discounting is very common in alternative mod-
els found in the financial and health economics literature. We stress that this utilitarian
flavour of the model should not be viewed as something necessary. Rather, it seems like
a natural starting point before introducing more complicating factors that may bring
the model closer to practical applications. However, it is important to keep in mind that
the definition of the utility function will have a large impact on which boundaries that
are optimal.
Finally, we note that the numerical methods described in Section 5 can certainly be
improved upon. A more comprehensive investigation regarding which algorithms are
best suited for different types of free-boundary value problems would be valuable.
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A. Proof of Theorem 2.3
Proof. Uniqueness will be demonstrated by showing that if b¯S(r)≥ 0 solves the integral
equation (2.11), then b¯S(r) = bS(r) for r ∈ [0,1].
Define a value function corresponding to b¯S as
V¯ (r,y) =
∫ 1
r
E(r,y)
[
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)]
du, 0≤ r ≤ 1. (A.1)
By comparing the right hand sides of equations (2.11) and (A.1), it is then clear that if
b¯S solves equation (2.11),
V¯ (r,±b¯S(r)) = (1− r)hξ(r, b¯S(r)) = G˜(r, b¯S(r)), r ∈ [0,1]. (A.2)
Moreover, since the process (r,Sr)r has the strong Markov property, it follows that for
any stopping time ρ ∈ [r,1],
V¯ (r,y) = E(r,y)
[
V¯ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
. (A.3)
That b¯S(r) = bS(r), 0≤ r ≤ 1, will now be shown in four steps.
Step 1 (V¯ (r,y) = G˜(r,y) if |y| ≥ b¯S(r)):
Let |y| ≥ b¯S(r) and ρ = inf{u ≥ r : |Su| ≤ b¯S(u)}∧ 1. This definition of ρ ensures that
ρ ∈ [r,1] and that the process (Sr), when started in (r,y), will always stay above b¯S(u)
for u ∈ [r,ρ]. Equations (A.2) and (A.3) now yield
V¯ (r,y) = E(r,y)
[
V¯ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
= E(r,y)
[
G˜(ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)du
]
= G˜(r,y),
where the last equality follows by Dynkin’s formula applied to G˜(ρ,Sρ).
Step 2 (V¯ (r,y)≤ V˜ (r,y)):
Since V¯ (r,y) = G˜(r,y)≤ V˜ (r,y) if |y| ≥ b¯S(r) by step 1, it remains to show the inequality
under the assumption that |y| < b¯S(r). Applying equation (A.3) to the stopping time
ρ= inf{u≥ r : |Su| ≥ b¯S(u)}∧1 gives
V¯ (r,y) = E(r,y)
[
V¯ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
= E(r,y)
[
G˜(ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)0du
]
≤ V˜ (r,y).
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Step 3 (b¯S ≤ bS):
Let y ≥ max(bS(r), b¯S(r)). Using steps 1 and 2 and applying equation (A.3) to the
stopping time ρ= inf{u≥ r : |Su| ≤ bS(u)}∧1 yields
G˜(r,y) = V¯ (r,y) = E(r,y)
[
V¯ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
≤ E(r,y)
[
V˜ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
.
Similarly, the value function V˜ satisfies
G˜(r,y) = V˜ (r,y) = E(r,y)
[
V˜ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I(|Su| ≥ bS(u)) du
]
= E(r,y)
[
V˜ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)du
]
.
It follows that
E(r,y)
[∫ ρ
r
hξ(u, |Su|)
(
1− I
(
|Su| ≥ b¯S(u)
))
du
]
≤ 0,
and hence
P(r,y)
(
|Su| ≥ b¯S(u) for all u such that r ≤ u≤ ρ
)
= 1.
Since both b¯S and bS are assumed to be continuous, this can only be the case if b¯S ≤ bS .
Step 4 (b¯S ≥ bS):
Using step 2 and applying equation (A.3) to the stopping time ρ = inf{u ≥ r : |Su| ≥
bS(u)}∧1 (which is the optimal one for the original problem) yields
V˜ (r,y)≥ V¯ (r,y) = E(r,y)
[
V¯ (ρ,Sρ)
]
+E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
.
Since |Sρ|= bS(ρ)≥ b¯S(ρ) by step 3, step 1 implies that V¯ (ρ,Sρ) = G˜(ρ,Sρ), so that
V˜ (r,y)≥ V˜ (r,y) +E(r,y)
[∫ ρ
r
hξ(u, |Su|)I
(
|Su| ≥ b¯S(u)
)
du
]
.
The above implies that
P(r,y)
(
|Su| ≤ b¯S(u) for all u such that r ≤ u≤ ρ
)
= 1.
Since both b¯S and bS are assumed to be continuous, this can only hold if b¯S ≥ bS .
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B. Details on the caluclations for Theorem 6.2
Let Vˆ0(s,y) be the value function corresponding to the modified reward function Gˆ0 and
define z = z(s) = c+q (s)/
√−s. The boundary conditions of continuous and smooth fit
which Vˆ0 must satisfy on c+q (s) are
Vˆ0 = Gˆ0 =−z(−s)−1/2(1 + 2q)−2(−s)1/2(1 + q)
(
φ(z)−z (1−Φ(z))),
∂yVˆ0 = ∂yGˆ0 =−(−s)−1(1 + 2q) + 2(1 + q)(1−Φ(z)) .
Setting η = (1 + q)/(1 + 2q), these may be rewritten as
Vˆ0(s,c+q (s))
1 + 2q =−z(−s)
−1/2−2(−s)1/2η(φ(z)−z (1−Φ(z))), (B.1)
∂yVˆ0(s,c+q (s))
1 + 2q =−(−s)
−1 + 2η (1−Φ(z)) . (B.2)
Following Chernoff and Petkau (1981, Appendix A5), we assume that c+q (s) satisfies
ln(−s) = z2/2 +a−1 ln(z) +a0 +o(1), s→−∞, (B.3)
for some constants a−1 and a0 (to be determined), and that
Vˆ0(s,c+q (s))
1 + 2q ∼ f0
(
(−s)1/2z
)
,
∂yVˆ0(s,c+q (s))
1 + 2q ∼ f
′
0
(
(−s)1/2z
)
, s→−∞.
The function f0 is defined as
f0(y) =−2ln(y
2)
y
, giving f ′0(y) = 2
(
ln(y2)−2
y2
)
.
In what follows, we’ll make use the well known asymptotic results for the normal density
and distribution functions given below:
1−Φ(z) = φ(z)
(
z−1 +o(z−1)
)
, z→∞, (B.4)
φ(z)−z(1−Φ(z)) = φ(z)
(
z−2 +o(z−2)
)
, z→∞. (B.5)
Use of equation (B.5) in equation (B.1) now gives
−2ln(−s) + ln(z
2)
(−s)1/2z ∼−z(−s)
−1/2−2(−s)1/2ηφ(z)
(
z−2 +o(z−2)
)
⇐⇒
−2z−1
(−s)1/2
(
ln(−s) + ln(z2)
)
∼ −2z
−1
(−s)1/2
(
z2/2 + (−s)ηφ(z)
(
z−1 +o(z−1)
))
.
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ln(−s) + ln(z2) should now be matched against z2/2 + (−s)ηφ(z)(z−1 +o(z−1)). Inser-
tion of equation (B.3) into these expressions leads to
ln(−s) + ln(z2) = z2/2 +a−1 ln(z) +a0 +o(1) + ln(z2), (B.6)
z2/2 + (−s)ηφ(z)
(
z−1 +o(z−1)
)
= z2/2 + z
a−1−1ea0eo(1)η (1 +o(1))√
2pi
. (B.7)
Similarly, use of equation (B.4) in equation (B.2) gives
2
(
ln(−s) + ln(z2)−2
(−s)z2
)
∼−(−s)−1 + 2ηφ(z)
(
z−1 +o(z−1)
)
⇐⇒
2z−2
(−s)
(
ln(−s) + ln(z2)−2
)
∼ 2z
−2
(−s)
(
(−z2/2) + (−s)z2ηφ(z)
(
z−1 +o(z−1)
))
,
and ln(−s)+ln(z2)−2 should be matched against (−z2/2)+(−s)z2ηφ(z)(z−1 +o(z−1)).
Insertion of equation (B.3) on both sides leads to
ln(−s) + ln(z2)−2 = z2/2 +a−1 ln(z) +a0 +o(1) + ln(z2)−2, (B.8)
(−z2/2) + (−s)z2ηφ(z)
(
z−1 +o(z−1)
)
= (−z2/2) +η z
a−1+1ea0eo(1) (1 +o(1))√
2pi
. (B.9)
By choosing a−1 = 1 and a0 = (1/2) ln(2pi) + ln(η−1), the coefficients of the dominating
terms (involving z2) on the right hand sides of equations (B.6) and (B.7), and that of
equations (B.8) and (B.9), will agree. Insertion of these coefficient values in equation
(B.3) leads to
φ
(
c+q /
√−s
)
c+q /
√−s ∼ η
−1(−s)−1, s→−∞.
By the assumption (B.3), as s→−∞, c+q /
√−s→∞. Hence, an application of equation
(B.4) yields
1−Φ(c+q /
√−s)∼ η−1(−s)−1, s→−∞,
which in turn implies
c+q =
√−sΦ−1
(
1 +η−1s−1(1 +o(1))
)
, s→−∞.
From this point it is easily shown, using the following asymptotic properties for the nor-
mal inverse distribution function and the Lambert W function (Dominici, 2003; Corless
et al., 1996),
Φ−1(1−x)∼
√
W
( 1
2pix2
)
, x→ 0, W (x)∼ ln
(
x
ln(x)
)
, x→∞,
that we may in fact write c+q ∼
√−sΦ−1 (1 +η−1s−1) , s→−∞.
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